UPDATE 1-LifeMD to offer Novo's Ozempic at $499 a month to eligible US cash-paying customers

(Adds background in paragraphs 2-3) Sept 30 (Reuters) – Telehealth firm LifeMD said on Tuesday it would partner with Novo Nordisk to offer its diabetes drug Ozempic at $499 per month to eligible U.S. patients, including insured people whose plans do not cover GLP-1 therapies. Novo offers Ozempic for $499 a month to eligible cash-paying patients via its own pharmacy, NovoCare, and through tie-ups with telehealth platforms. Patients can book virtual visits, complete testing and get medicine shipped with order tracking through LifeMD. (Reporting by Padmanabhan Ananthan in Bengaluru; Editing by Shilpi Majumdar)

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)